BLS tracks a representative sample of prescription drug costs on the market, measuring the actual amount people pay for the drugs, not list prices, according to Business Insider.
While healthcare experts cannot confidently identify the reason behind this spike, Yale economist Fiona Scott Morton, PhD, believes pricey biologic drugs may be fueling costs, reports Marketplace.
More articles on supply chain:
Tenn. high school opens medical device machinery lab
Sen. Blumenthal urges DOJ to reject Mylan settlement
TPC names ROi preferred supply chain partner: 3 things to know
